MAT

GATC Health Welcomes the FDA Modernization Act 2.0, Allowing New Drug Candidates to Bypass Animal Testing Using Computer Modeling

Retrieved on: 
Wednesday, January 25, 2023
Safety, Artificial intelligence, Legislation, AlphaGo, DeepMind, Human, Congress, Biomedical engineering, Biomedicine, GATC, IBM Watson, FDA, Health, MAT, Drug discovery, Animal, Federal Food, Drug, and Cosmetic Act, Risk, Disease, Biology, Research, Science, Pharmaceutical industry, Medical device

IRVINE, Calif., Jan. 25, 2023 /PRNewswire/ -- GATC Health, a science and technology company revolutionizing drug discovery and disease prediction using artificial intelligence (AI), today announced that the FDA Modernization Act 2.0 signed into law in December 2022, ends an FDA mandate that experimental drugs must be tested on animals before they are used on humans in clinical trials.  The new legislation allows emerging technologies, including GATC's computer modeling that predicts a potential drugs safety and efficacy in humans, to be used to advance drug leads to human trials without the requirement of animal testing.

Key Points: 
  • FDA Modernization Act 2.0 is expected to create more demand for GATC's drug discovery and development platform.
  • In 1938, Congress passed the U.S. Federal Food, Drug, and Cosmetic Act, mandating animal toxicity testing.
  • Since then, science and data has shown that animal testing is highly inconsistent in predicting toxic responses in humans.
  • GATC's computer simulation models use human biological components to more accurately predict medical and biological outcomes than animal testing.

GATC Health to Speak at the Opioid Settlement Abatement Summit in Washington DC

Retrieved on: 
Wednesday, January 25, 2023
ETSU, Artificial intelligence, Municipality, Bureau of Justice Assistance, Emergency department, Georgetown University, Corrections, Policy, Georgetown University School of Medicine, United States Department of Justice, GATC, Addiction, Office of National Drug Control Policy, Volunteering, Volunteers of America, ONDCP, Private law, Hospital, Opioid, East Tennessee State University, Health, MAT, Drug discovery, Research, Science, Legal Services Corporation, Pharmaceutical industry

IRVINE, Calif., Jan. 24, 2023 /PRNewswire/ -- GATC Health Corp, a science and technology company revolutionizing drug discovery and disease prediction using artificial intelligence (AI), today announced that Tyrone Lam, COO of GATC Health, will present the company's fentanyl abatement drug candidates that were identified by GATC's AI-based drug discovery and development platform. The novel created by GATC are currently in preclinical drug evaluation studies. Guidelines allocated a portion of the Opioid Abatement Settlement funds for research and development, which includes GATC's opioid addiction abatement projects.

Key Points: 
  • The novel created by GATC are currently in preclinical drug evaluation studies.
  • Guidelines allocated a portion of the Opioid Abatement Settlement funds for research and development, which includes GATC's opioid addiction abatement projects.
  • The Opioid Settlement Abatement Summit – Model Guidance for States, Counties, Municipalities and Tribes will take place on Thursday January 26th, 2023 at Georgetown University and virtually, and focus on providing model abatement guidance for states, counties, municipalities and tribes to effectively plan for, implement and track opioid settlement funds.
  • Equally prominent will be highlighting the successes and challenges of ongoing opioid litigations and the policies that have evolved to help reduce the harms associated with drug addiction.

Medexus Announces Another Record Quarter with Fiscal Q3 2023 Revenue of US$28.7 Million, a 35% Increase Over Fiscal Q3 2022

Retrieved on: 
Wednesday, February 8, 2023
Marketing, MBA, SEDAR, Federal Court of Canada, Roberto Menassi, TSX, IQVIA, Webcast, Federal court, Calendar, Patient, Patent, Adjustment, MAT, Investment, Growth, PAP, Research, Pharmaceutical industry, Video game, Security (finance), Risk management, Internet service provider

TORONTO and CHICAGO, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals (Medexus) (TSX: MDP) (OTCQX: MEDXF) today announced its operating and financial results and provided a business update for the company’s third fiscal quarter ended December 31, 2022 (the company’s fiscal Q3 2023). All dollar amounts in this press release are in United States dollars unless specified otherwise.

Key Points: 
  • Record total revenue of $28.7 million, a year-over-year increase of 35%, and a quarter-over-quarter increase of 4%.
  • Record Adjusted EBITDA* of $5.2 million, a year-over-year improvement of $3.3 million and a quarter-over-quarter increase of $1.0 million.
  • Cash and cash equivalents of $9.3 million (with $10.1 million of total available liquidity) at end of fiscal Q3 2023.
  • Medexus will host a conference call at 8:00 AM Eastern Time on Thursday, February 9, 2023, to discuss the company’s operating and financial results and corporate updates for fiscal Q3 2023.

Dong-A ST Demonstrates Therapeutic Equivalence Between DMB-3115 and Stelara in Global Phase III

Retrieved on: 
Tuesday, January 17, 2023
Health, FDA, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, MAT, Ustekinumab, Safety, IQVIA, Psoriasis, Ulcerative colitis, Intas Biopharmaceuticals, Patient, Week, Psoriasis Area and Severity Index, Psoriatic arthritis, III, USD, EMA, Pharmaceutical industry, Vaccine, EU

Dong-A ST (President and CEO: Min-young Kim) (KRX:170900) announced on January 16th that therapeutic equivalence and safety were established between DMB-3115 and Stelara, the reference drug, in global phase III.

Key Points: 
  • Dong-A ST (President and CEO: Min-young Kim) (KRX:170900) announced on January 16th that therapeutic equivalence and safety were established between DMB-3115 and Stelara, the reference drug, in global phase III.
  • DMB-3115 global phase III first kicked off in the US back in 2021 and then in eight European countries, including Poland, Estonia, and Latvia, with a total patient number of 605 over 52 weeks.
  • Patients with moderate to severe chronic plaque psoriasis were treated with DMB-3115 or Stelara PFS to compare efficacy, safety, and immunogenicity.
  • DMB-3115 and Stelara demonstrated therapeutic equivalence when looking at percent change from baseline in PASI (Psoriasis Area and Severity Index) at Week 8 and Week 12.

MAT Act Signed Into Law, NABP Applauds Benefits for Overdose Prevention and Recovery Support

Retrieved on: 
Thursday, January 5, 2023
Doctor of Pharmacy, Legislation, Friends, National Association, Office of National Drug Control Policy, Public health, MS, House, Democrat, Republican, Senate, Buprenorphine, Organization, White House, Omnibus spending bill, Pharmacist, Opioid use disorder, NABP, MAT, Policy, White, OUD, Hospital, Drug, Pharmacy, Congress, Consolidated Appropriations Act, 2021, SUD, Pharmaceutical industry

The MAT Act will help turn the tide of the overdose crisis by saving thousands of lives from overdoses and supporting long-term recovery from OUD.

Key Points: 
  • The MAT Act will help turn the tide of the overdose crisis by saving thousands of lives from overdoses and supporting long-term recovery from OUD.
  • By passing the MAT Act, Congress has acted to prevent future overdose deaths and support people with SUD in securing recovery.
  • NABP is one of nearly 550 organizations that called on Congress and the White House to pass the MAT Act.
  • The MAT Act was among the most broadly supported pieces of overdose prevention legislation introduced this session.

Minovia Therapeutics appoints Maha Radhakrishnan, Chief Medical Officer at Biogen, as board member

Retrieved on: 
Thursday, January 5, 2023
Partnership, GMP, Central nervous system, Degenerative disease, Therapy, Cardiology, Drug development, Research, UnitedHealth Group, Pearson syndrome, MAT, Patient, Bristol Myers Squibb, Ophthalmology, Astellas Pharma, Neurology, Safety, Entrepreneurship, Science Translational Medicine, Rheumatology, Internal medicine, Diabetes, Psychiatry, Pharmaceutical industry, Biogen, Cephalon

TIRAT HACARMEL, Israel, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Minovia Therapeutics (Minovia) , a clinical-stage company focused on developing novel Mitochondrial Augmentation Technology (MAT) to fight mitochondrial diseases, has announced a Board appointment.

Key Points: 
  • TIRAT HACARMEL, Israel, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Minovia Therapeutics (Minovia) , a clinical-stage company focused on developing novel Mitochondrial Augmentation Technology (MAT) to fight mitochondrial diseases, has announced a Board appointment.
  • Maha Radhakrishnan, M.D., joins the board at a time in which the company advances clinical programs in primary mitochondrial diseases and hematological disorders associated with mitochondrial dysfunction.
  • As a trained physician, Maha is a senior leader with extensive pharmaceutical and biotech experience covering clinical development, post-marketing regulatory activities, medical affairs, safety, and reimbursement requirements.
  • Maha is the Chief Medical Officer of Biogen, and in her previous roles, she served as Senior Vice President and Global Head of Medical, Primary Care Business Unit at Sanofi, Senior Vice President and Head of Worldwide Medical at Bioverativ Therapeutics Inc., and Head of Europe & Canada Medical and US Medical at Biogen.

Minovia Therapeutics Reports First Clinical Data Demonstrating Disease-Modifying Efficacy and Safety of Mitochondrial Augmentation Therapy in Pediatric Patients with Primary Mitochondrial Diseases

Retrieved on: 
Wednesday, December 21, 2022
Immunodeficiency, Blood, Food, Therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Failure, Quality of life, Pearson syndrome, DNA, Mitochondrion, Trial of the century, HSPC, Disease, Sheba Medical Center, KSS, MAT, Patient, Health, Weight gain, Microdeletion syndrome, Tel HaShomer, A-DNA, Safety, Science Translational Medicine, Sideroblastic anemia, Pearson, Hematology, Stem cell, Vaccine, Pharmaceutical industry, Medical imaging

WOBURN, Mass. and HAIFA, Israel, Dec. 21, 2022 (GLOBE NEWSWIRE) -- Minovia Therapeutics, a clinical-stage global biotechnology company, today announced that the findings of the first clinical use of mitochondrial augmentation therapy (MAT) platform to treat pediatric patients with primary mitochondrial diseases have been published in Science Translational Medicine. The study was conducted in collaboration with global leaders in the field of hematology and primary mitochondrial disease at Sheba Medical Center (Tel Hashomer, Israel).

Key Points: 
  • and HAIFA, Israel, Dec. 21, 2022 (GLOBE NEWSWIRE) -- Minovia Therapeutics, a clinical-stage global biotechnology company, today announced that the findings of the first clinical use of mitochondrial augmentation therapy (MAT) platform to treat pediatric patients with primary mitochondrial diseases have been published in Science Translational Medicine.
  • Single, large deletions in mitochondrial DNA (mtDNA) can lead to a variety of devastating diseases, including Pearson Syndrome and Kearns-Sayre Syndrome (KSS).
  • Minovia is developing MAT to treat Primary Mitochondrial Diseases such as Pearson syndrome, as well as other mitochondrially-related sideroblastic anemias.
  • "We believe these findings lay important groundwork for further development of MAT and future clinical trials to demonstrate the effectiveness and safety of MAT in patients with primary mitochondrial disorders and other diseases.

Shatterproof Applauds the Passage of the MATE Act to Expand Addiction Education

Retrieved on: 
Friday, December 23, 2022
Public Policy, Government, White House, Federal Government, Public Policy, General Health, Health, Mental Health, Healthcare Reform, Congressional News, Views, Well, Education, Doctor of Nursing Practice, Addiction, Mental health, Legislation, School, Pain, SUD, Substance-related disorder, American College, Health, Voices, Omnibus Appropriations Act, 2009, SMART Recovery, House, Drug Safety, Organization, Buprenorphine, National Council, Drug Enforcement Administration, Federation, National Safety Council, American Society of Addiction Medicine, Drug, Opioid use disorder, Research, MAT, Patient, Representative, Curriculum, Society, Oxford, OUD, Maintenance, Student, American College of Medical Toxicology, MATE, Congress, Suds, Louisiana House of Representatives, University, Addiction medicine, DEA, Speech disorder, Pharmaceutical industry, Medicine, The 39 Clues

Shatterproof applauds the passage of the Medication Access and Training Expansion (MATE) Act (H.R.

Key Points: 
  • Shatterproof applauds the passage of the Medication Access and Training Expansion (MATE) Act (H.R.
  • Passage of the MAT Act along with the MATE Act will enable better access to life-saving treatment.
  • The MATE Act mainstreams addiction medical education on SUDs across the nation’s medical educational programs.
  • Shatterproof worked closely with the American Society of Addiction Medicine on the passing of the MATE Act.

InventHelp Inventor Develops Sanitary Accessory for Use at Laundromats (FED-2442)

Retrieved on: 
Thursday, December 29, 2022
MAT, Mobile, Sale, Clothing, Multimedia, Self-service laundry, Dry cleaning, Publishing

My design eliminates worry and contamination when transferring laundry or using the baskets at a Laundromat."

Key Points: 
  • My design eliminates worry and contamination when transferring laundry or using the baskets at a Laundromat."
  • The patent-pending invention provides a laundry accessory that would ease the transfer of clothing between machines when using a Laundromat.
  • It also offers a more sanitary way to use laundry baskets at the Laundromat.
  • The invention features a portable design that is easy to use so it is ideal for individuals who use Laundromats.

Crossroads's twin Grand Openings offer new hope in fight against opioid addiction in Murfreesboro and Hermitage, Tennessee

Retrieved on: 
Tuesday, December 27, 2022
Topical steroid withdrawal, Televisit, Patient, Family, Toxicology, Opioid use disorder, Anxiety, Tennessee Association of Christian Schools, Depression, Old Hickory Boulevard, Health, Opioid, Insurance, CDC, Call centre, FDA, Multimedia, Medicaid, MAT, Practitioner, TennCare, NIH, Puerto Rico Administration of Mental Health and Anti-Addiction Services, Drug, Pharmaceutical industry, Hospital

GREENVILLE, S.C., Dec. 27, 2022 /PRNewswire/ -- Crossroads Treatment Centers, the leader in Office-Based Opioid Treatment (OBOT), opened its newest addiction treatment centers in the Nashville area on Nov. 14. The new center in Murfreesboro hosted a grand opening from 10 a.m. – 12 p.m., and the new center in Hermitage hosted a grand opening from 2 p.m. – 4 p.m. The events were free to attend and open to the public. Crossroads opened another center in Memphis the following day.

Key Points: 
  • GREENVILLE, S.C., Dec. 27, 2022 /PRNewswire/ -- Crossroads Treatment Centers , the leader in Office-Based Opioid Treatment (OBOT), opened its newest addiction treatment centers in the Nashville area on Nov. 14.
  • "We are proud to provide our proven approach to treating opioid addiction in the underserved communities of Murfreesboro and Hermitage," said Lisa Connell, Tennessee regional director for Crossroads.
  • Crossroads Treatment Centers now has more than eight locations in Tennessee serving more than 1,400 patients statewide.
  • Their new opioid treatment centers in Nashville, Murfreesboro and Memphis bring hope to so many of our neighbors and loved ones struggling with addiction.